Chronic Malignancies Working Party Educational Event on MDS
21st ESH-EBMT Training Course
6th Training Course for Paediatricians & Paediatric Nurses on HSCT in Children and Adolescents
21 January 2017 in Paris, France
On 21st of January 2017 the Chronic Malignancy Working Party of EBMT performed in Paris, hosted by Marie Robin from Saint Louis Hospital an MDS Educational session titled: “New insights into pathogenesis and treatment of MDS”.
The Meeting was well attended and about 70 participants listened and discussed with the leaders in the field about the new insights into the pathogenesis of MDS and the new development in the treatment with focus on new options including allogeneic stem cell transplantation.
First S. Kordasti from UK and N. Dulphy from Paris gave a common lecture of the role of the immunity in MDS progression and treatment evolving how immunity can work in MDS especially how immunity can be influence progression. The more recent discovery of somatic mutations in MDS was presented by C. Koenecke from Germany who reported about the impact of somatic mutation on outcomes after allogeneic stem cell transplantation. He could nicely demonstrate on more than 300 patients that p53 mutation is the major molecular risk factor for worse outcome after allogeneic stem cell transplantation in MDS.
I. Yakoub-Agha from France gave an exciting lecture about graft versus MDS-effect from bench to clinic and how the graft versus leukemia effect in MDS can be targeted without an obvious higher risk of graft versus host disease.
In addition A. Bacigalupo from Italy presented updated results about haplo-identical donor stem cell transplant in MDS, suggesting that haplo-identical stem cell transplantation may result in similar outcome like in patients with HLA-identical sibling or complete matched unrelated donor.
The role of allogeneic SCT in very high risk patients was presented by U. Platzbecker from Germany who included in his lectures also how iron overloaded patient can be treated successfully without having higher therapy related mortality as reported in the literature.
In addition, P. Fenaux from France gave an excellent overview about innovative treatments in higher MDS patients, who are not eligible for an allogeneic stem cell transplantation, highlighting that the non-transplant options in high risk MDS patients are still very limited.
Last but not least T. De Witte summarized the EBMT-ELN consensus guidelines for MDS transplantation which were recently published in Blood in collaboration with international experts.
Overall the meeting was an enormous success. It was well received by the attendees and the CMWP. Thanks Marie Robin for hosting and all the faculty members for their excellent presentations.
Nicolaus Kröger, CMWP Chair
4-6 May 2017 in Saggart (Dublin), Ireland
Chairs: Carlo Dufour, Mohamad Mohty, Gert Ossenkoppele, Robert Zeiser
This year marked the 21st anniversary of the ESH-EBMT Training Course on Haemopoietic Stem Cell Transplantation that Eliane Gluckman, Jane Apperley, Alois Gratwohl, Enric Carreras and Tamas Masszi brought to maturity and international recognition over the years.
In 2017, Carlo Dufour, Mohamad Mohty, Gert Ossenkoppele, Robert Zeiser assumed leadership of the meeting. They designed it as a platform for scientific discussion and international networking, and they invited a prestigious faculty of international experts.
The excellent comprehensive scientific programme placed emphasis on both biology and clinical aspects, mostly presented in plenary format. However, there were also multiple opportunities for face to face interaction with international authorities during small, informal sessions. These included “Junior Podiums”, a new addition to the meeting that gave selected participants the opportunity to present case reports and to receive guidance from members of the faculty. The meeting also included popular Meet the Expert breakfast and dinner sessions, each organized on a specific theme. Poster sessions were also organized.
Our thanks go to the Chairmen and faculty of this year’s Training Course and to the wonderful group of participants who registered for the meeting. Over 140 people participated in the meeting this year with 23% coming to join us from outside of Europe.
We warmly acknowledge the support of the sponsors.
From left to right: Carlo Dufour, Gert Ossenkoppele, Robert Zeiser
8-10 June 2017 in Copenhagen, Denmark
The EBMT Pediatric Diseases and the Inborn Errors Working Parties as well as the EBMT Paediatric Nurses held their joint educational meeting in Copenhagen, Denmark, in June 2017.
Marianne Ifversen and her team from the Paediatric Stem Cell Transplant and Immune Deficiency Unit of the University Hospital Rigshospitalet welcomed nearly 100 nurses, physicians and medical students to the wonderful midsummer Capital of Denmark.
48 nurses from 16 countries, 41 physicians from 17 countries and 11 medical students from 4 countries represented a multinational audience and faculty.
The cutting edge physicians’ educational program focused on donor and graft selection, GvHD, efficacy and toxicity of HSCT, the emerging immune system, cellular therapies, disease specific controversies (transplant? Yes or no) and long-term toxicities.
The up-to-date nurses educational program covered the improvement of quality of live during SCT, complications during and after SCT, supportive therapies as well as the care for children with life-threatening complications.
The Chair of the PDWP Peter Bader opened this educational giving a broad overview of the history of bone marrow transplantation from its early beginnings in Seattle in the 1960ies to the current broadly available treatment options of modern HSCT.
Thereafter Mary Slatter explained and discussed current principles of the modern donor- und graft selection hierarchy, which is one major backbone of this fascinating treatment option.
Anita Lawitschka updated the audience on the most important side effect of modern HSCT, which still is an often-unsolved problem: GvHD. She focused on the long-term burdens of chronic GvHD, its classification and treatment options.
Franco Locatelli, who touched nearly every aspect of pediatric HSCT during his career, was the one to give a fascinating overview of the new colorful world of cellular therapies.
Of course CAR T-cell therapy is a “must” of an up-to-date HSCT-educational: Jochen Buechner updated the audience with promising current results and developments of the worldwide multicenter single-arm open-label ELIANA trial to treat children with relapsed and refractory B-precusor ALL using the fascinating genetically modified chimeric-antigen-receptor (CAR) T-cells.
Andy Gennery, former chair of the IEWP, hijacked his audience into the world of primary immune deficiencies and gave a broad overview on diagnostics, pathophysiology, treatment as well as late effects of the in general relatively unknown family of DNA repair disorders. Here he focused particularly on Fanconi Anemia.
Our extremely busy and well-organized EBMT nurses group discussed cutting-edge topics: Susanne Molin showed how to tackle pain during and after SCT in children. Hilde Ulving gave insights into the clinical signs and treatment options of bronchiolitis obliterans in paediatrics and Daphna Hutt, the new chair of the EBMT Paediatric Nurses Group, gave a lecture on graft failure during SCT. Our extremely active former chair of the EBMT Paediatric Nurses Group Eugenia Trigoso discussed the specific features of nursing care for patients, who receive extracorporal photopheresis to treat chronic GvHD.
Numerous new contacts and friendships between physicians, nurses, medical students and the international faculty will further strengthen the pediatric HSCT family in Denmark as well as all over the world.
Taken together Marianne Ifversen and her team represented a perfect host to this important and up-to-date PDWP and IEWP-driven educational event.
Training Course for Paediatricians & Paediatric Nurses on HSCT in Children and Adolescents will be held in 2019.
Peter Bader and Andre Willasch on behalf of the PDWP